Abstract
Cardiovascular diseases (CVDs) have been documented as one of the leading causes of deaths with an estimated death toll of 17 million. Early detection may reduce the high risk of sudden deaths associated with it. Current biomedical sensing processes vastly rely on antigen-antibody based detection processes, which have limitations in point-of-care applications. In this work, we developed an integrated microfluidic platform for the simultaneous detection up to six clinical samples using a highly specific aptamer for recognizing the protein followed by an antibody-based chemiluminescence assay for the detection of CVDs biomarker, N-terminal pro-b-type natriuretic peptide (NT-proBNP) in less than 30 minutes. A fully automated on-chip detection of NT-proBNP was performed using only 15 µL of clinical samples from each patient. It may serve a promising tool for CVDs monitoring and diagnosis.